SCHEMBL20989092

SCHEMBL20989092

O=C(NCCNC(=O)C1CCN(C(=O)COc2ccccc2)CC1)c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.56
KMT2A Q03164 1/20 0.56
KDM4E B2RXH2 6/20 0.54
MAPT P10636 2/20 0.54
SMN1; SMN2 Q16637 6/20 0.53
POLB P06746 1/20 0.51
ALDH1A1 P00352 4/20 0.50
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
LMNA P02545 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
HPGD P15428 2/20 0.50
PKM P14618 1/20 0.50
EPHX2 P34913 1/20 0.50
USP2 O75604 1/20 0.49
GAA P10253 1/20 0.49
TP53 P04637 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
CHRM2 P08172 1/20 0.48
CHRM5 P08912 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29532260 0.86 NPC1 (0.62) MEN1KMT2AKDM4EMAPTSMN1; SMN2
SCHEMBL20989077 0.81 MEN1 (0.58) MEN1KMT2AKDM4EMAPTSMN1; SMN2
SCHEMBL29532316 0.81 SMN1; SMN2 (0.62) MEN1KMT2AKDM4EMAPTSMN1; SMN2
SCHEMBL20989171 0.81 POLB (0.63) KMT2AKDM4ESMN1; SMN2POLBALDH1A1
SCHEMBL20989192 0.80 RECQL (0.58) MEN1KMT2AKDM4EMAPTSMN1; SMN2
SCHEMBL29532645 0.79 SMN1; SMN2 (0.56) MEN1KMT2AKDM4EMAPTSMN1; SMN2
SCHEMBL20989076 0.79 SMN1; SMN2 (0.53) MEN1KMT2AMAPTSMN1; SMN2POLB
SCHEMBL29532384 0.78 SMN1; SMN2 (0.52) MEN1KMT2AKDM4EMAPTSMN1; SMN2
SCHEMBL20989104 0.78 MEN1 (0.53) MEN1KMT2AKDM4EMAPTSMN1; SMN2
SCHEMBL5367904 0.76 ME2 (0.56) MEN1KMT2AKDM4EMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190134056-A1 K-RAS MUTATIONS AND ANTAGONISTS THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOG (US) 2019-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190134056-A1 K-RAS MUTATIONS AND ANTAGONISTS KRAS, NRAS, HRAS MEN1 1465/4885KMT2A 2604/4885KDM4E 4410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.